Close Menu

NEW YORK (GenomeWeb) – Natera announced today that it has prices its $100 million common stock offering.

The San Carlos, California-based molecular diagnostics firm is offering 5,263,158 shares of common stock at $19 per share. Gross proceeds from the offering would be $100 million, however, the underwriters of the transaction have a 30-day option to purchase an additional 789,473 shares at the offering price.

JP Morgan, Cowen, and Piper Jaffray are acting as joint book-running managers for the offering. Baird and Canaccord Genuity are listed as co-managers for the offering.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.